UNIVERSITY OF SOUTHERN CALIFORNIA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Phase 1
Completed
- Conditions
- CancerCarcinoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 35
- Registration Number
- NCT00183742
- Locations
- 🇺🇸
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma
Phase 2
Completed
- Conditions
- Gastric AdenocarcinomaGastric Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 25
- Registration Number
- NCT00183911
- Locations
- 🇺🇸
U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Colon CancerColorectal Cancer
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 40
- Registration Number
- NCT00183833
- Locations
- 🇺🇸
USC/Norris Cancer Center, Los Angeles, California, United States
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck
Phase 2
Terminated
- Conditions
- Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 12
- Registration Number
- NCT00184028
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Phase 2
Terminated
- Conditions
- Esophageal Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 6
- Registration Number
- NCT00183807
- Locations
- 🇺🇸
U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7
- Registration Number
- NCT00184080
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
Phase 2
Terminated
- Conditions
- Melanoma
- Interventions
- Biological: Montanide ISA 51
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 23
- Registration Number
- NCT00184067
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Completed
- Conditions
- Esophageal NeoplasmsGastric Cancer
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 40
- Registration Number
- NCT00183872
- Locations
- 🇺🇸
University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center, Los Angeles, California, United States
Intensified Post Remission Therapy Containing PEG-Asparaginase
Phase 2
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 47
- Registration Number
- NCT00184041
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 76
- Registration Number
- NCT00183885
- Locations
- 🇺🇸
U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath